Wang Jin, Wei Hong-Juan, Mao Rui-Feng, Chang Xin
Department of Ultrasound Medicine, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing 211200, Jiangsu Province, China.
Neonatal Intensive Care Unit, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing 211200, Jiangsu Province, China.
World J Diabetes. 2024 Oct 15;15(10):2152-2156. doi: 10.4239/wjd.v15.i10.2152.
In this editorial, we commented on two articles published online in August and September 2024 in the , which focused on modifying the gut microbiota (GM) to prevent or delay the progression of diabetes mellitus (DM) and DM-related complications. Numerous studies, many of which are animal studies, have indicated the potential role of GM in the pathogenesis of DM. However, the detailed causality and mechanisms between GM and DM have not been fully clarified. Although there have been some reports of a potential role of modifying the GM in treating DM, most lack long-term observations and are not mechanistic. Additionally, the GM and its role in DM might vary among individuals; therefore, GM-targeted interventions should be individualized to realize their therapeutic potential.
在这篇社论中,我们对2024年8月和9月在线发表在《》上的两篇文章进行了评论,这两篇文章聚焦于通过调节肠道微生物群(GM)来预防或延缓糖尿病(DM)及其相关并发症的进展。众多研究,其中许多是动物研究,表明GM在DM发病机制中具有潜在作用。然而,GM与DM之间的详细因果关系和机制尚未完全阐明。尽管已有一些关于调节GM在治疗DM中潜在作用的报道,但大多数缺乏长期观察且没有涉及机制。此外,GM及其在DM中的作用可能因个体而异;因此,针对GM的干预措施应个体化,以实现其治疗潜力。